Use of risperidone in pervasive developmental disorders: A case series

Journal of Child and Adolescent Psychopharmacology

Volumn 6, Issue 3, 1996, Pages 177-190

  Fisman, Sandra ^a,b   Steele, Margaret ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CLOZAPINE; FENFLURAMINE; HALOPERIDOL; RISPERIDONE;

ADOLESCENT; ARTICLE; ATTENTION; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; FEMALE; HUMAN; MALE; OBSESSION; SCHOOL CHILD;

EID: 0029844153     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.1996.6.177     Document Type: Article

References (69)

1. Abramson RK, Wright HH, Carpenter R, Brennan W, Lumpuy O, Cole E, Young SR: Elevated blood serotonin in autistic probands and their first-degree relatives. J Autism Dev Disord 19:397-407, 1989
2. Alarcon RD, Johnson BR, Lucas JP: Paranoid and aggressive behavior in two obsessive-compulsive adolescents treated with clomipramine. J Am Acad Child Adolesc Psychiatry 30:999-1002, 1991
3. Alivir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine induced agranulocytosis: Incidence and risk factors in the United States. N Engl J Med 329:162-167, 1993
4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington (DC), American Psychiatric Association, 1980
5. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington (DC), American Psychiatric Association, 1994
6. Anderson GM: Monoamines in autism: An update of neurochemical research on a pervasive developmental disorder. Med Biol 65:67-74, 1987
7. Anderson GM, Freedman DX, Cohen DJ, Volkmar FR, Hoder EL, McPhedran P, Ruud BM, Hansen CR, Young JG: Whole blood serotonin autistic and normal subjects. J Child Psychol Psychiatry 28:885-900, 1987
8. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 141:1195-1202, 1984
9. Andreasen NC: Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry 39:784-788, 1982
10. Andreasen NC: The scale for the Assessment of Negative Symptoms (SANS). Iowa City (IA), 1983
11. Andreasen NC, Olsen S: Negative v positive schizophrenia: Definition and validation. Arch Gen Psychiatry 39:789-794, 1982
12. Baldessarini RJ, Teicher MH: Dosing of antipsychotics in pediatric populations [Editorial]. J Child Adolesc Psychopharmacol 1:1-3, 1995
13. Barthelemy C, Bruneau N, Cottet-Eymard JM: Urinary free and conjugated catecholamines and metabolites in autistic children. J Autism Dev Disorders 18:583-591, 1988
14. Bettes BA, Walker E: Positive and negative symptoms in psychotic and other psychiatrically disturbed children. J Child Psychol Psychiatry 28:555-568, 1987
15. Borison RL, Pathiraja AP, Diamond BI, Meibach RC: Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 281:213-218, 1992
16. Brasic JR, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, Kowalik S, Clark A, Tsaltas MO, Young JG: Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 44:1309-1312, 1994
17. Campbell M, Adams P, Perry R, Spencer EK: Tardive and withdrawal dyskinesias in autistic children: A prospective study. Psychopharmacol Bull 24:251-255, 1988a
18. Campbell M, Adams P, Samll AM; Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry 27:434-439, 1988b
19. Campbell M, Anderson LT, Meier M: A comparison of haloperidol, behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640-655, 1978
20. Casaer P, Walleghem D, Vandenbussche I, Huang ML, De Smedt G: Pharmacokinetics and safety of risperidone in autistic children. Pediatr Neurol 11:89, 1994
21. Chouinard G, Jones B, Remington G: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic inpatients. J Clin Psychopharmacol 13:25-40, 1993
22. Cohen DJ, Caparalo BK, Shaywitz BA, Bowers MB: Dopamine and serotonin metabolism in neuropsychiatrically disturbed children: CSF homovanillic acid and 5-hydroxyindoleacetic acid. Arch Gen Psychiatry 34:545-550, 1977
23. Cohen DJ, Shaywitz BA, Johnson WT, Bowers MB: Biogenic amines in autistic and atypical children: Cerebrospiral fluid measures of homovanillic and 5-hydroxyindolacetic acid. Arch Gen Psychiatry 31:845-853, 1974
24. Cook EH, Leventhal BL, Heller W, Metz J, Wainwright M, Freedman DX: Autistic children and their first-degree relatives: Relationships between serotonin and norepinephrine levels and intelligence. J Neuropsychiatry Clin Neurosci 2:268-274, 1990
25. Cook EH, Rowlett R, Jaselskis C, Leventhal BL: Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 31:739-745, 1992
26. Cozza SJ, Edison DL: Risperidone in adolescents. J Am Acad Child Adolesc Psychiatry 33:1211, 1994
27. Creak M: Schizophrenic syndrome in childhood: Further progress of a working party. Dev Med Child Neurol 6:530-535, 1963
28. Demb HB: Risperidone in young children with pervasive developmental disorder and other developmental disabilities. J Child Adolesc Psychopharmacol 6:79-80, 1996
29. Eufemia PD, Finocchiaro R, Celli M, Viozzi L, Monteleone D, Giardini O: Low serum tryptophan to large neutral amino acids ratio in idiopathic infantile autism. Biomed Pharmacother 49:288-292, 1995
30. Fisman S, Reniers D, Diaz P: Erythromycin interaction with risperidone or clomipramine in an adolescent. J Child Adolesc Psychopharmacol 6:133-138, 1996
31. Garreau B, Barthelemy C, Jouve J, Bruneau N, Muh JP, Lelor G: Urinary homovanillic acid levels of autistic children. Dev Med Child Neurol 30:93-98, 1988
32. Geller E, Ritvo ER, Freeman BJ, Yuwiler A: Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 307:165-169, 1982
33. Ghaziuddin M, Tsai L, Ghaziuddin N: Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry 30:508-509, 1991
34. Gillberg C, Svennerholm L: CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry 151:89-94, 1987
35. Gillberg C, Svennerholm L, Hamilton-Hellberg C: Childhood psychosis and monoamine metabolites in spinal fluid. J Autism Dev Disord 13:383-396, 1983
36. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL: A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441-447, 1993
37. Haller E, Binder RL: Clozapine and seizures. Am J Psychiatry 146(8):1069-1071, 1990.
38. Hameury L, Roux S, Barthelemy C, Adrien JL, Desombre H, Sauvage D, Carreau B, Lelord G: Qualified multidimensional assessment of autism and other pervasive developmental disorders: Application for bioclinical research. Eur Child Adolesc Psychiatry 4:123-135, 1995
39. 2 antagonistic properties. J Pharmacol Exp Therapeutics 244:685-693, 1988
40. Kay SR: Positive and Negative Symptoms in Schizophrenia. New York, Brunner Mazel, 1991
41. Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the Positive and Negative Symptom Scale for Schizophrenia. Psychiatry Res 23:99-110, 1987
42. Kolvin I: Studies in the childhood psychoses: I. Diagnostic criteria and classification. Br J Psychiatry 118:381-384, 1971
43. Kuperman S, Beeghly JH, Burns TL, Tsai LY: Serotonin relationships of autistic probands and their first degree relatives. J Am Acad Child Psychiatry 24:186-190, 1985
44. Leventhal BL, Cook EH, Morford M, Ravitz A, Freedman DX: Relationships of whole blood serotonin and plasma norepinephrine within families of autistic children. J Autism Dev Disord 20:499-511, 1990
45. Leysen JE, Gommeren W, Ens A, De Chaffoy De Courcelles D, Stoof JC, Janssen PAJ: Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Therapeutics 247:661-670, 1988
46. Lombroso PJ, Scahill L, King RA, Lynch KA, Chappell PB, Peterson BS, McDougle CJ, Leckman JF: Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report. J Am Acad Child Adolesc Psychiatry 34:1147-1152, 1995
47. Mandoki MW: Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 5:49-67, 1995
48. Martineau J, Barthelemy C, Jouve J, Muh JP, Lelord G: Monoamines (serotonin and catecholamines) and their derivatives in infantile autism: Age related changes and drug effects. Dev Med Clin Neurol 34:593-603, 1992
49. McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH: Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 5:273-282, 1995
50. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-O'Brien D, Nielsen J, Bregman J, Cohen DJ: Clomipramine in autism: Preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry 31:746-750, 1992
51. McEvoy JP: Efficacy of risperidone on positive features of schizophrenia. J Clin Psychiatry 55:18-21, 1994
52. Minderaa RB, Anderson GM, Volkmar FR, Akkerhuis GW, Cohen DH: Neurochemical study of dopamine functioning in autistic and normal subjects. J Am Acad Child Adolesc Psychiatry 28:190-194, 1989a
53. Minderaa RB, Anderson GM, Volkmar FR, Akkerhuis GW, Cohen DH: Noradrenergic and adrenergic function in autism. Biol Psychiatry 36:237-241, 1994
54. Minderaa RB, Anderson GM, Volkmar FR, Harcherick D, Akkerhuis GW, Cohen DJ: Whole blood serotonin and tryptophan in autism: Temporal stability and the effects of medication. J Autism Dev Disord 19:129-136, 1989b
55. Narayan M, Srinath S, Anderson GM, Meundi DB: Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyin-doleacetic acid in autism. Biol Psychiatry 33:630-635, 1993
56. Owens DGC: Extrapyramidal side effects and tolerability of risperidone: A review. J Clin Psychiatry 55:29-35, 1994
57. Piven J, Tsai G, Nehme E, Coyle JT, Chase GA, Folstein SE: Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord 21:51-59, 1991
58. Purdon SE, Wilson L, Labelle A, Jones BDW: Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 39:400-405, 1994
59. Quintana H, Keshavan M: Risperidone in children and adolescents with schizophrenia [Case study]. J Am Acad Child Adolesc Psychiatry 34:1292-1296, 1995
60. Ritvo ER, Freeman BJ, Yuwiler A, Geller E, Schroth P, Yokota A, Mason-Brothers A, August GJ, Klykylo W, Leventhal B, Lewis K, Piggott L, Realmuto G, Stubbs EG, Umansky R: Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at 9 medical centers. Psychopharmacol Bull 22:133-140, 1986
61. Rolf LH, Haarmann FY, Grotemeyer KH, Kehrer H: Serotonin and amino acid content in platelets of autistic children. Acta Psychiatr Scand 87:312-316, 1993
62. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB: A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 35:537-544, 1996
63. Schooler NR: Negative symptoms in schizophrenia. J Clin Psychiatry 55:22-28, 1994
64. Shaffer D, Gould M, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983
65. Simeon JG, Carrey NJ, Wiggins DM, Millin RP, Hosenbocus SN: Risperidone effects in treatment-resistant adolescents: Preliminary case report. J Child Adolesc Psychopharmacol 5:69-79, 1995
66. Stamenkovic M, Aschauer H, Kasper S: Risperidone for Tourette's syndrome. Lancet 344:1577-1578, 1994
67. Szatmari P, Bartolucci G, Bremner R: Asperger's syndrome and autism: Comparisons on early history and outcome. Dev Med Child Neurol 31:709-720, 1989
68. Young GJ, Kavanaugh ME, Anderson GM, Shaywitz BA, Cohen DJ: Clinical neurochemistry of autism and associated disorders. J Autism Dev Disord 12:147-165, 1982
69. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL: Serotonergic responsivity in obsessive-compulsive disorder: Effects of chronic clomipramine treatment. Arch Gen Psychiatry 45:167-172, 1988